

**This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.**

**The data included in this report reflect the results of a systematic search and review of data on a range of indicators reflecting the extent of services provided to people who inject drugs.**

**These data have been searched, reviewed and extracted according to decision rules developed by the Reference Group.**

**Some data have been adjusted to facilitate estimates of standard indicators across countries.**

**Details of the process for searching, grading and including data, along with their interpretation, are detailed in:**

Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R, et al. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and national coverage. *The Lancet* 2010. DOI:10.1016/S0140-6736(10)60232-2.

**For more information on the Reference Group, please go to: [www.IDURefGroup.Com](http://www.IDURefGroup.Com)**

| Section   | Page      |
|---|-----------|
| Estimated number of people who inject drugs and number of injectors who are living with HIV | 4         |
| <b>1. Needle and syringe programs (NSPs)</b>  | <b>5</b>  |
| NSP 1: Availability of NSPs   |           |
| NSP 2: Number of NSP sites  |           |
| NSP 3: Number of pharmacy sites where needles and syringes are available for purchase       |           |
| NSP 4: Total number of sites where needles and syringes are available                       |           |
| NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period                  |           |
| NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period            |           |
| NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period              |           |
| <b>2. Opioid substitution programs (OST)</b>  | <b>10</b> |
| OST 1: Availability of opioid substitution treatment (OST)                                  |           |
| OST 2: Availability of methadone maintenance treatment (MMT)                                |           |
| OST 3: Availability of buprenorphine maintenance treatment (BMT)                            |           |
| OST 4: Availability of other forms of agonist OST   |           |
| OST 5: Dose and duration of MMT   |           |
| OST 6: Dose and duration of BMT   |           |
| OST 7: Total number of all sites providing OST  |           |
| OST 8: Number of sites providing MMT  |           |
| OST 9: Number of sites providing BMT  |           |
| OST 10: Number of sites providing other forms of agonist OST                                |           |
| OST 11: Number of all clients in any OST at a single point in time                          |           |
| OST 12: Number of all clients in MMT at a single point in time                              |           |
| OST 13: Number of all clients in BMT at a single point in time                              |           |
| OST 14: Number of all clients in other forms of OST at a single point in time               |           |
| OST 15: Number of IDUs in any OST at a single point in time                                 |           |
| OST 16: Number of IDUs in MMT at a single point in time                                     |           |
| OST 17: Number of IDUs in BMT at a single point in time                                     |           |
| OST 18: Number of IDUs in other forms of OST at a single point in time                      |           |
| OST 19: Number of all clients receiving any OST in a 12 month period                        |           |
| OST 20: Number of all clients receiving MMT in a 12 month period                            |           |
| OST 21: Number of all clients receiving BMT in a 12 month period                            |           |
| OST 22: Number of all clients receiving other forms of OST in a 12 month period             |           |
| OST 23: Number of IDUs receiving any OST in a 12 month period                               |           |
| OST 24: Number of IDUs receiving MMT in a 12 month period                                   |           |

| <b>Section</b>   | <b>Page</b> |
|--|-------------|
| OST 25: Number of IDUs receiving BMT in a 12 month period  |             |
| OST 26: Number of IDUs receiving other forms of OST in a 12 month period   |             |
| <b>3. Other Drug Treatment (ODT)</b>   | <b>23</b>   |
| <hr/>  |             |
| ODT 1: Detoxification  |             |
| ODT 1.1: Number of sites providing detoxification  |             |
| ODT 1.2: Number of IDUs receiving detoxification   |             |
| ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time    |             |
| ODT 2: Residential Rehabilitation  |             |
| ODT 2.1: Number of sites providing residential rehabilitation  |             |
| ODT 2.2: Number of IDUs in residential rehabilitation  |             |
| ODT 2.3: Number of all clients in residential rehabilitation   |             |
| ODT 3: Outpatient psychosocial support, counselling and psychotherapy  |             |
| ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy                 |             |
| ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment        |             |
| ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment |             |
| ODT 4: Peer-based support groups   |             |
| ODT 4.1: Number of sites providing peer-based support groups   |             |
| ODT 4.2: Number of IDUs in peer-based support groups   |             |
| ODT 4.3: Number of all clients in peer-based support groups  |             |
| ODT 5: Drug treatment (treatment type not specified)   |             |
| ODT 5.1: Number of sites providing unspecified drug treatment  |             |
| ODT 5.2: Number of IDUs receiving unspecified drug treatment   |             |
| ODT 5.3: Number of all clients receiving unspecified drug treatment  |             |
| ODT 6: Drug treatment in prisons   |             |
| ODT 6.1: Number of drug treatment sites located in prisons   |             |
| ODT 6.2: Number of IDUs receiving drug treatment in prisons  |             |
| ODT 6.3: Number of all clients receiving drug treatment in prisons   |             |
| ODT 7: Compulsory drug treatment   |             |
| ODT 7.1: Number of compulsory detention sites for drug use   |             |
| ODT 7.2: Number of IDUs in compulsory detention sites for drug use   |             |
| ODT 7.3: Number of all drug users in compulsory detention sites for drug use                                     |             |
| <b>4. HIV testing and counselling (T&amp;C)</b>  | <b>37</b>   |
| <hr/>  |             |
| T&C 1: Availability of HIV T&C   |             |
| T&C 2: Number of sites providing HIV T&C that specifically targets IDUs  |             |

| <b>Section</b>  | <b>Page</b> |
|---|-------------|
| T&C 3: Number of T&C sites providing HIV T& to the general population and also accessible to IDUs |             |
| T&C 4: Number of individual IDUs who were tested for HIV in a 12 month period                     |             |
| T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result    |             |
| <b>5. Anti-retro-viral (ARV) treatment</b>  | <b>40</b>   |
| <hr/>   |             |
| ARV 1: Number of sites providing ARV treatment  |             |
| ARV 2: Number of IDUs receiving ARVs at a single point in time                                    |             |
| ARV 3: Restrictions on IDUs' access to ARVs   |             |
| <b>6. Condoms</b>   | <b>43</b>   |
| <hr/>   |             |
| Condoms 1: Availability of condom programs targeting IDUs   |             |
| Condoms 2: Number of sites distributing condoms to IDUs   |             |
| Condoms 3: Number of individual IDUs receiving condoms  |             |
| Condoms 4: Number of condoms distributed to IDUs  |             |

## Paraguay (Latin America)

### Estimated number of people who inject drugs and number of injectors who are living with HIV

|   |   |     |      |
|---|---|-----|------|
| Estimated prevalence of IDU among general population aged 15-64 years (%) | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Year of IDU prevalence estimate   |   |     |      |
| Reference for IDU prevalence estimate                                     | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| Estimated prevalence of HIV among people who inject (%)                   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Year of HIV prevalence among IDU estimate                                 | 2006  |     |      |
| Reference for HIV prevalence among IDU estimate                           | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.   |     |      |
| General population 15-64 years of age in 2008                             | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated IDU population in 2008  | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Estimated number of IDUs living with HIV in 2008                          | Low   | Mid | High |
|   | NK  | NK  | NK   |

## 1. Needle and syringe programs (NSPs)

### NSP 1: Availability of NSPs

|  |   |
|--|---|
| Are NSPs available?  | Yes                                     |
| Comments   |   |
| Most recent year of documentation                                | 2009                                    |
| Reference  | See references for other NSP indicators |
| When were NSPs first introduced?                                 |   |
| Reference  |   |
| Are needles and syringes available for purchase from pharmacies? |   |
| Most recent year of documentation                                |   |
| Reference  |   |

### NSP 2: Number of NSP sites

|   |   |     |      |
|---|---|-----|------|
| Data reported   | 3 sites   |     |      |
| Year of reported data   | 2009  |     |      |
| Reference   | WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.   |     |      |
| Adjustments   |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 | 3   |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                          | 3 868 998 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Number of NSP sites per 1000 IDUs  | Low   | Mid | High |
|   | NK  | NK  | NK   |

**NSP 3: Number of pharmacy sites where needles and syringes are available for purchase**

|   |     |     |      |
|---|-----|-----|------|
| Data reported   |     |     |      |
| Year of reported data   |     |     |      |
| Reference   |     |     |      |
| Adjustments   |     |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data                          |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Number of pharmacy sites per 1000 IDUs                                       | Low | Mid | High |
|   | NK  | NK  | NK   |

**NSP 4: Total number of sites where needles and syringes are available**

|   |     |     |      |
|---|-----|-----|------|
| Total number (NSP sites + Pharmacy sites)   |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data                          |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low | Mid | High |
|   |     |     |      |
| INDICATOR: Total number of sites per 1000 IDUs  | Low | Mid | High |
|   |     |     |      |

## NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period

|   |   |     |      |
|---|---|-----|------|
| Data reported   | NSP present but number not known  |     |      |
| Year of reported data   | 2008  |     |      |
| Reference   | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.  |     |      |
| Adjustments   |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 | NK  |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                          | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs in contact with NSPs in a 12 month period                 | Low   | Mid | High |
|   | NK  | NK  | NK   |

## NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period

|  |   |     |      |
|--|---|-----|------|
| Data reported  | NSP present but number not known  |     |      |
| Year of reported data  | 2008  |     |      |
| Reference  | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.  |     |      |
| Adjustments  |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                      | NK  |     |      |
| IDU prevalence estimate (%)  | Low   | Mid | High |
|  | NK  | NK  | NK   |
| Reference  | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                               | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)      | Low   | Mid | High |
|  | NK  | NK  | NK   |
| INDICATOR: Number of NSP occasions of service (client contacts) in a 12 month period per IDU | Low   | Mid | High |
|  | NK  | NK  | NK   |

## NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period

|  |   |            |             |
|--|---|------------|-------------|
| <b>Data reported</b>   | NSP present but number not known  |            |             |
| <b>Year of reported data</b>   | 2008  |            |             |
| <b>Reference</b>   | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,  |            |             |
| <b>Adjustments</b>   |   |            |             |
| <b>Final/Adjusted data (to be used as indicator numerator)</b>                                 | NK  |            |             |
| <b>IDU prevalence estimate (%)</b>   | <b>Low</b>  | <b>Mid</b> | <b>High</b> |
|  | NK  | NK         | NK          |
| <b>Reference</b>   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |            |             |
| <b>General population 15-64 years of age at year of reported data</b>                          | 3 778 358 (source: UN Population Division, 2009)  |            |             |
| <b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b> | <b>Low</b>  | <b>Mid</b> | <b>High</b> |
|  | NK  | NK         | NK          |
| <b>INDICATOR: Total number of needles/syringes distributed in a 12 month period per IDU</b>    | <b>Low</b>  | <b>Mid</b> | <b>High</b> |
|  | NK  | NK         | NK          |

**NSP: All documents reviewed**

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

**2. Opioid substitution treatment (OST)****OST 1: Availability of opioid substitution treatment (OST)**

|   |  |
|---|--|
| Are any forms of agonist OST available? | No   |
| Comments                                |  |
| Most recent year of documentation       | 2008   |
| Reference                               | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,. |
| When was agonist OST first available?   |  |
| Reference                               |  |

**OST 2: Availability of methadone maintenance treatment (MMT)**

|                                   |  |
|-----------------------------------|--|
| Is MMT available?                 | No   |
| Comments                          |  |
| Most recent year of documentation | 2008   |
| Reference                         | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,. |
| When was MMT first available?     |  |
| Reference                         |  |

**OST 3: Availability of buprenorphine maintenance treatment (BMT)**

|                                   |  |
|-----------------------------------|--|
| Is BMT available?                 | No   |
| Comments                          |  |
| Most recent year of documentation | 2008   |
| Reference                         | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,. |
| When was BMT first available?     |  |
| Reference                         |  |

**OST 4: Availability of other forms of agonist OST**

|   |  |
|---|--|
| Are other forms of OST available?             | No   |
| Comments                                      |  |
| Most recent year of documentation             | 2008   |
| Reference                                     | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,. |
| When were other forms of OST first available? |  |
| Reference                                     |  |

## OST 5: Dose and duration of MMT

|  |  |
|--|--|
| Average/standard maintenance dose of MMT |  |
| Comments                                 |  |
| Year                                     |  |
| Reference                                |  |
| Average/standard duration of MMT (range) |  |
| Comments                                 |  |
| Year                                     |  |
| Reference                                |  |

## OST 6: Dose and duration of BMT

|  |  |
|--|--|
| Average/standard maintenance dose of BMT |  |
| Comments                                 |  |
| Year                                     |  |
| Reference                                |  |
| Average/standard duration of BMT (range) |  |
| Comments                                 |  |
| Year                                     |  |
| Reference                                |  |

## OST 7: Total number of all sites providing OST

|   |   |     |      |
|---|---|-----|------|
| Data reported   | OST not available   |     |      |
| Year of reported data   | 2008  |     |      |
| Reference   | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments   |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 | 0   |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                          | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Number of OST sites per 1000 IDUs  | Low   | Mid | High |
|   | 0   | 0   | 0    |

## OST 8: Number of sites providing MMT

|   |   |     |      |
|---|---|-----|------|
| Data reported   | OST not available   |     |      |
| Year of reported data   | 2008  |     |      |
| Reference   | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments   |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 | 0   |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                          | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Number of MMT sites per 1000 IDUs  | Low   | Mid | High |
|   | NK  | NK  | NK   |

## OST 9: Number of sites providing BMT

|   |   |     |      |
|---|---|-----|------|
| Data reported   | OST not available   |     |      |
| Year of reported data   | 2008  |     |      |
| Reference   | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments   |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 | 0   |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                          | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Number of BMT sites per 1000 IDUs  | Low   | Mid | High |
|   | NK  | NK  | NK   |

## OST 10: Number of sites providing other forms of agonist OST

|  |   |            |             |
|--|---|------------|-------------|
| <b>Data reported</b>   | OST not available   |            |             |
| <b>Year of reported data</b>   | 2008  |            |             |
| <b>Reference</b>   | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,  |            |             |
| <b>Adjustments</b>   |   |            |             |
| <b>Final/Adjusted data (to be used as indicator numerator)</b>                                 | 0   |            |             |
| <b>IDU prevalence estimate (%)</b>   | <b>Low</b>  | <b>Mid</b> | <b>High</b> |
|  | NK  | NK         | NK          |
| <b>Reference</b>   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |            |             |
| <b>General population 15-64 years of age at year of reported data</b>                          | 3 778 358 (source: UN Population Division, 2009)  |            |             |
| <b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b> | <b>Low</b>  | <b>Mid</b> | <b>High</b> |
|  | NK  | NK         | NK          |
| <b>INDICATOR: Number of sites providing other forms of OST per 1000 IDUs</b>                   | <b>Low</b>  | <b>Mid</b> | <b>High</b> |
|  | 0   | 0          | 0           |

## OST 11: Number of all clients in any OST at a single point in time

|  |   |     |      |
|--|---|-----|------|
| Data reported  | OST not available   |     |      |
| Year of reported data  | 2008  |     |      |
| Reference  | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments  |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)  | 0   |     |      |
| IDU prevalence estimate (%)  | Low   | Mid | High |
|  | NK  | NK  | NK   |
| Reference  | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data   | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)                            | Low   | Mid | High |
|  | NK  | NK  | NK   |
| INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST at census date : 100 IDUs | Low   | Mid | High |
|  | 0   | 0   | 0    |

## OST 12: Number of all clients in MMT at a single point in time

|  |   |     |      |
|--|---|-----|------|
| Data reported  | OST not available   |     |      |
| Year of reported data  | 2008  |     |      |
| Reference  | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments  |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)  | 0   |     |      |
| IDU prevalence estimate (%)  | Low   | Mid | High |
|  | NK  | NK  | NK   |
| Reference  | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data   | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)                        | Low   | Mid | High |
|  | NK  | NK  | NK   |
| INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT at census date : 100 IDUs | Low   | Mid | High |
|  | 0   | 0   | 0    |

## OST 13: Number of all clients in BMT at a single point in time

|  |   |     |      |
|--|---|-----|------|
| Data reported  | OST not available   |     |      |
| Year of reported data  | 2008  |     |      |
| Reference  | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments  |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)  | 0   |     |      |
| IDU prevalence estimate (%)  | Low   | Mid | High |
|  | NK  | NK  | NK   |
| Reference  | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data   | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)                        | Low   | Mid | High |
|  | NK  | NK  | NK   |
| INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT at census date : 100 IDUs | Low   | Mid | High |
|  | 0   | 0   | 0    |

## OST 14: Number of all clients in other forms of OST at a single point in time

|   |   |     |      |
|---|---|-----|------|
| Data reported   | OST not available   |     |      |
| Year of reported data   | 2008  |     |      |
| Reference   | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments   |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)   | 0   |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data  | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)                                       | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST at census date : 100 IDUs | Low   | Mid | High |
|   | 0   | 0   | 0    |

## OST 15: Number of IDUs in any OST at a single point in time

|   |   |     |      |
|---|---|-----|------|
| Data reported   | OST not available   |     |      |
| Year of reported data   | 2008  |     |      |
| Reference   | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments   |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 | 0   |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                          | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs in OST at a single point in time                          | Low   | Mid | High |
|   | 0   | 0   | 0    |

## OST 16: Number of IDUs in MMT at a single point in time

|   |   |     |      |
|---|---|-----|------|
| Data reported   | OST not available   |     |      |
| Year of reported data   | 2008  |     |      |
| Reference   | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments   |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 | 0   |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                          | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs in MMT at a single point in time                          | Low   | Mid | High |
|   | 0   | 0   | 0    |

## OST 17: Number of IDUs in BMT at a single point in time

|   |   |     |      |
|---|---|-----|------|
| Data reported   | OST not available   |     |      |
| Year of reported data   | 2008  |     |      |
| Reference   | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments   |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 | 0   |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                          | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs in BMT at a single point in time                          | Low   | Mid | High |
|   | 0   | 0   | 0    |

## OST 18: Number of IDUs in other forms of OST at a single point in time

|   |   |     |      |
|---|---|-----|------|
| Data reported   | OST not available   |     |      |
| Year of reported data   | 2008  |     |      |
| Reference   | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments   |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 | 0   |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                          | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs in other forms of OST at a single point in time           | Low   | Mid | High |
|   | 0   | 0   | 0    |

## OST 19: Number of all clients receiving any OST in a 12 month period

|  |   |     |      |
|--|---|-----|------|
| Data reported  | OST not available   |     |      |
| Year of reported data  | 2008  |     |      |
| Reference  | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments  |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)  | 0   |     |      |
| IDU prevalence estimate (%)  | Low   | Mid | High |
|  | NK  | NK  | NK   |
| Reference  | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data   | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)                                  | Low   | Mid | High |
|  | NK  | NK  | NK   |
| INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST in a 12 month period : 100 IDUs | Low   | Mid | High |
|  | 0   | 0   | 0    |

## OST 20: Number of all clients receiving MMT in a 12 month period

|  |   |     |      |
|--|---|-----|------|
| Data reported  | OST not available   |     |      |
| Year of reported data  | 2008  |     |      |
| Reference  | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments  |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)  | 0   |     |      |
| IDU prevalence estimate (%)  | Low   | Mid | High |
|  | NK  | NK  | NK   |
| Reference  | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data   | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)                              | Low   | Mid | High |
|  | NK  | NK  | NK   |
| INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT in a 12 month period : 100 IDUs | Low   | Mid | High |
|  | 0   | 0   | 0    |

## OST 21: Number of all clients receiving BMT in a 12 month period

|  |   |     |      |
|--|---|-----|------|
| Data reported  | OST not available   |     |      |
| Year of reported data  | 2008  |     |      |
| Reference  | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments  |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)  | 0   |     |      |
| IDU prevalence estimate (%)  | Low   | Mid | High |
|  | NK  | NK  | NK   |
| Reference  | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data   | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)                              | Low   | Mid | High |
|  | NK  | NK  | NK   |
| INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT in a 12 month period : 100 IDUs | Low   | Mid | High |
|  | 0   | 0   | 0    |

## OST 22: Number of all clients receiving other forms of OST in a 12 month period

|   |   |     |      |
|---|---|-----|------|
| Data reported   | OST not available   |     |      |
| Year of reported data   | 2008  |     |      |
| Reference   | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments   |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)   | 0   |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data  | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST in a 12 month period : 100 IDUs | Low   | Mid | High |
|   | 0   | 0   | 0    |

## OST 23: Number of IDUs receiving any OST in a 12 month period

|   |   |     |      |
|---|---|-----|------|
| Data reported   | OST not available   |     |      |
| Year of reported data   | 2008  |     |      |
| Reference   | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments   |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 | 0   |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                          | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs receiving OST in a 12 month period                        | Low   | Mid | High |
|   | 0   | 0   | 0    |

## OST 24: Number of IDUs receiving MMT in a 12 month period

|   |   |     |      |
|---|---|-----|------|
| Data reported   | OST not available   |     |      |
| Year of reported data   | 2008  |     |      |
| Reference   | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments   |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 | 0   |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                          | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs receiving MMT in a 12 month period                        | Low   | Mid | High |
|   | 0   | 0   | 0    |

## OST 25: Number of IDUs receiving BMT in a 12 month period

|   |   |     |      |
|---|---|-----|------|
| Data reported   | OST not available   |     |      |
| Year of reported data   | 2008  |     |      |
| Reference   | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments   |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 | 0   |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                          | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs receiving BMT in a 12 month period                        | Low   | Mid | High |
|   | 0   | 0   | 0    |

## OST 26: Number of IDUs receiving other forms of OST in a 12 month period

|   |   |     |      |
|---|---|-----|------|
| Data reported   | OST not available   |     |      |
| Year of reported data   | 2008  |     |      |
| Reference   | Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association.,.   |     |      |
| Adjustments   |   |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 | 0   |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                          | 3 778 358 (source: UN Population Division, 2009)  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs receiving other forms of OST at a single point in time    | Low   | Mid | High |
|   | 0   | 0   | 0    |

**OST: All documents reviewed**

No references recorded

**3. Other drug treatment (ODT)****ODT 1 - Detoxification****ODT 1.1: Number of sites providing detoxification**

|   |     |     |      |
|---|-----|-----|------|
| Is detoxification available?  |     |     |      |
| Number of sites - data reported   |     |     |      |
| Year of reported data   |     |     |      |
| Reference   |     |     |      |
| Adjustments   |     |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data                          |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Number of detoxification sites per 1000 IDUs                                 | Low | Mid | High |
|   | NK  | NK  | NK   |

**ODT 1.2: Number of IDUs receiving detoxification**

|   |     |     |      |
|---|-----|-----|------|
| Data reported   |     |     |      |
| Year of reported data   |     |     |      |
| Reference   |     |     |      |
| Adjustments   |     |     |      |
| Final/Adjusted data for 12 month period (to be used as indicator numerator)             |     |     |      |
| Final/Adjusted data for single point in time (to be used as indicator numerator)        |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data                          |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs in detoxification in a 12 month period                    | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs in detoxification at a single point in time               | Low | Mid | High |
|   | NK  | NK  | NK   |

### ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time

|  |     |     |      |
|--|-----|-----|------|
| Data reported  |     |     |      |
| Year of reported data  |     |     |      |
| Reference  |     |     |      |
| Adjustments  |     |     |      |
| Final/Adjusted data for 12 month period (to be used as indicator numerator)                            |     |     |      |
| Final/Adjusted data for single point in time (to be used as indicator numerator)                       |     |     |      |
| IDU prevalence estimate (%)  | Low | Mid | High |
|  |     |     |      |
| Reference  |     |     |      |
| General population 15-64 years of age at year of reported data   |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)                | Low | Mid | High |
|  | NK  | NK  | NK   |
| INDICATOR: Ratio of number of all clients in detoxification in a 12 month period : number of IDUs      | Low | Mid | High |
|  | NK  | NK  | NK   |
| INDICATOR: Ratio of number of all clients in detoxification at a single point in time : number of IDUs | Low | Mid | High |
|  | NK  | NK  | NK   |

## ODT 2 - Residential rehabilitation

## ODT 2.1: Number of sites providing residential rehabilitation

|   |     |     |      |
|---|-----|-----|------|
| Is residential rehabilitation present?  |     |     |      |
| Number of sites - data reported   |     |     |      |
| Year of reported data   |     |     |      |
| Reference   |     |     |      |
| Adjustments   |     |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data                          |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Number of residential rehabilitation sites per 1000 IDUs                     | Low | Mid | High |
|   | NK  | NK  | NK   |

## ODT 2.2: Number of IDUs in residential rehabilitation

|   |     |     |      |
|---|-----|-----|------|
| Data reported   |     |     |      |
| Year of reported data   |     |     |      |
| Reference   |     |     |      |
| Adjustments   |     |     |      |
| Final/Adjusted data for 12 month period (to be used as indicator numerator)             |     |     |      |
| Final/Adjusted data for single point in time (to be used as indicator numerator)        |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data                          |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs in residential rehabilitation in a 12 month period        | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs in residential rehabilitation at a single point in time   | Low | Mid | High |
|   | NK  | NK  | NK   |

## ODT 2.3: Number of all clients in residential rehabilitation

|   |     |     |      |
|---|-----|-----|------|
| Data reported   |     |     |      |
| Year of reported data   |     |     |      |
| Reference   |     |     |      |
| Adjustments   |     |     |      |
| Final/Adjusted data for 12 month period (to be used as indicator numerator)   |     |     |      |
| Final/Adjusted data for single point in time (to be used as indicator numerator)                                      |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data  |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)                               | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Ratio of number of all drug users in residential rehabilitation in a 12 month period : number of IDUs      | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Ratio of number of all drug users in residential rehabilitation at a single point in time : number of IDUs | Low | Mid | High |
|   | NK  | NK  | NK   |

## ODT 3 - Outpatient psychosocial support, counselling and psychotherapy

## ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy treatment

|  |     |     |      |
|--|-----|-----|------|
| Is outpatient psychosocial support, counselling or psychotherapy present?                              |     |     |      |
| Number of sites - data reported  |     |     |      |
| Year of reported data  |     |     |      |
| Reference  |     |     |      |
| Adjustments  |     |     |      |
| Final/Adjusted data (to be used as indicator numerator)  |     |     |      |
| IDU prevalence estimate (%)  | Low | Mid | High |
|  |     |     |      |
| Reference  |     |     |      |
| General population 15-64 years of age at year of reported data   |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)                | Low | Mid | High |
|  | NK  | NK  | NK   |
| INDICATOR: Number of outpatient psychosocial support, counselling or psychotherapy sites per 1000 IDUs | Low | Mid | High |
|  | NK  | NK  | NK   |

## ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment

|   |     |     |      |
|---|-----|-----|------|
| Data reported   |     |     |      |
| Year of reported data   |     |     |      |
| Reference   |     |     |      |
| Adjustments   |     |     |      |
| Final/Adjusted data for 12 month period (to be used as indicator numerator)   |     |     |      |
| Final/Adjusted data for single point in time (to be used as indicator numerator)  |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data  |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)   | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs in outpatient psychosocial support, counselling or psychotherapy in a 12 month period             | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs receiving outpatient psychosocial support, counselling or psychotherapy at a single point in time | Low | Mid | High |
|   | NK  | NK  | NK   |

### ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment

|  |     |     |      |
|--|-----|-----|------|
| Data reported  |     |     |      |
| Year of reported data  |     |     |      |
| Reference  |     |     |      |
| Adjustments  |     |     |      |
| Final/Adjusted data for 12 month period (to be used as indicator numerator)  |     |     |      |
| Final/Adjusted data for single point in time (to be used as indicator numerator)   |     |     |      |
| IDU prevalence estimate (%)  | Low | Mid | High |
|  |     |     |      |
| Reference  |     |     |      |
| General population 15-64 years of age at year of reported data   |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)  | Low | Mid | High |
|  | NK  | NK  | NK   |
| INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy in a 12 month period : number of IDUs      | Low | Mid | High |
|  | NK  | NK  | NK   |
| INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy at a single point in time : number of IDUs | Low | Mid | High |
|  | NK  | NK  | NK   |

## ODT 4 - Peer-based support groups

## ODT 4.1: Number of peer-based support groups sites

|   |   |     |      |
|---|---|-----|------|
| Are Peer-based support groups present?  | Yes   |     |      |
| Number of sites - data reported   | 13 NA meetings per week   |     |      |
| Year of reported data   | 2008  |     |      |
| Reference   | Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.   |     |      |
| Adjustments   | Assumed each meeting per week occurs at a separate location   |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 | 13  |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                          | 3 778 358 null  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Number of peer-based support groups sites per 1000 IDUs                      | Low   | Mid | High |
|   | NK  | NK  | NK   |

## ODT 4.2: Number of IDUs in peer-based support groups

|   |   |     |      |
|---|---|-----|------|
| Data reported   | Narcotics Anonymous present but number not known  |     |      |
| Year of reported data   | 2008  |     |      |
| Reference   | Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.   |     |      |
| Adjustments   |   |     |      |
| Final/Adjusted data for 12 month period (to be used as indicator numerator)             | NK  |     |      |
| Final/Adjusted data for single point in time (to be used as indicator numerator)        | NK  |     |      |
| IDU prevalence estimate (%)   | Low   | Mid | High |
|   | NK  | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                          | 3 778 358 null  |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs in peer-based support groups in a 12 month period         | Low   | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs in peer-based support groups at a single point in time    | Low   | Mid | High |
|   | NK  | NK  | NK   |

## ODT 4.3: Number of all clients in peer-based support groups

|   |   |            |             |
|---|---|------------|-------------|
| <b>Data reported</b>  | Narcotics Anonymous present but number not known  |            |             |
| <b>Year of reported data</b>  | 2008  |            |             |
| <b>Reference</b>  | Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.   |            |             |
| <b>Adjustments</b>  |   |            |             |
| <b>Final/Adjusted data for 12 month period (to be used as indicator numerator)</b>  | NK  |            |             |
| <b>Final/Adjusted data for single point in time (to be used as indicator numerator)</b>                                     | NK  |            |             |
| <b>IDU prevalence estimate (%)</b>  | <b>Low</b>  | <b>Mid</b> | <b>High</b> |
|   | NK  | NK         | NK          |
| <b>Reference</b>  | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |            |             |
| <b>General population 15-64 years of age at year of reported data</b>   | 3 778 358 null  |            |             |
| <b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>                              | <b>Low</b>  | <b>Mid</b> | <b>High</b> |
|   | NK  | NK         | NK          |
| <b>INDICATOR: Ratio of number of all drug users in peer-based support groups in a 12 month period : number of IDUs</b>      | <b>Low</b>  | <b>Mid</b> | <b>High</b> |
|   | NK  | NK         | NK          |
| <b>INDICATOR: Ratio of number of all drug users in peer-based support groups at a single point in time : number of IDUs</b> | <b>Low</b>  | <b>Mid</b> | <b>High</b> |
|   | NK  | null       | null        |

## ODT 5 - Drug treatment (treatment type not specified)

## ODT 5.1: Number of drug treatment sites (treatment type not specified)

|   |     |     |      |
|---|-----|-----|------|
| Type of drug treatment available  |     |     |      |
| Number of sites - data reported   |     |     |      |
| Year of reported data   |     |     |      |
| Reference   |     |     |      |
| Adjustments   |     |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data                          |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Number of drug treatment sites per 1000 IDUs                                 | Low | Mid | High |
|   | NK  | NK  | NK   |

## ODT 5.2: Number of IDUs in drug treatment (treatment type not specified)

|   |     |     |      |
|---|-----|-----|------|
| Data reported   |     |     |      |
| Year of reported data   |     |     |      |
| Reference   |     |     |      |
| Adjustments   |     |     |      |
| Final/Adjusted data for 12 month period (to be used as indicator numerator)                                     |     |     |      |
| Final/Adjusted data for single point in time (to be used as indicator numerator)                                |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data  |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)                         | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined in a 12 month period      | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined at a single point in time | Low | Mid | High |
|   | NK  | NK  | NK   |

## ODT 5.3: Number of all clients in drug treatment (treatment type not specified)

|   |     |     |      |
|---|-----|-----|------|
| Data reported   |     |     |      |
| Year of reported data   |     |     |      |
| Reference   |     |     |      |
| Adjustments   |     |     |      |
| Final/Adjusted data for 12 month period (to be used as indicator numerator)   |     |     |      |
| Final/Adjusted data for single point in time (to be used as indicator numerator)  |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data  |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)   | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined in a 12 month period : number of IDUs      | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined at a single point in time : number of IDUs | Low | Mid | High |
|   | NK  | NK  | NK   |

## ODT 6 - Drug treatment in prisons

## ODT 6.1: Number of prison drug treatment sites

|                                    |  |
|------------------------------------|--|
| Type of drug treatment in prisons? |  |
| Number of sites - data reported    |  |
| Year of reported data              |  |
| Reference                          |  |
| Adjustments                        |  |
| Final/Adjusted data                |  |

## ODT 6.2: Number of IDUs in drug treatment in prisons

|  |  |
|--|--|
| Data reported                                |  |
| Year of reported data                        |  |
| Reference                                    |  |
| Adjustments                                  |  |
| Final/Adjusted data for 12 month period      |  |
| Final/Adjusted data for single point in time |  |

## ODT 6.3: Number of all clients in drug treatment in prisons

|  |  |
|--|--|
| Data reported                                |  |
| Year of reported data                        |  |
| Reference                                    |  |
| Adjustments                                  |  |
| Final/Adjusted data for 12 month period      |  |
| Final/Adjusted data for single point in time |  |

## ODT 7 - Compulsory detention as response to drug use

## ODT 7.1: Number of compulsory detention sites for drug use

|   |     |     |      |
|---|-----|-----|------|
| Number of sites - data reported   |     |     |      |
| Year of reported data   |     |     |      |
| Reference   |     |     |      |
| Adjustments   |     |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data                          |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Number of compulsory detention sites for drug use per 1000 IDUs              | Low | Mid | High |
|   | NK  | NK  | NK   |

## ODT 7.2: Number of IDUs in compulsory detention sites for drug use

|  |     |     |      |
|--|-----|-----|------|
| Data reported  |     |     |      |
| Year of reported data  |     |     |      |
| Reference  |     |     |      |
| Adjustments  |     |     |      |
| Final/Adjusted data for 12 month period (to be used as indicator numerator)                        |     |     |      |
| Final/Adjusted data for single point in time (to be used as indicator numerator)                   |     |     |      |
| IDU prevalence estimate (%)  | Low | Mid | High |
|  |     |     |      |
| Reference  |     |     |      |
| General population 15-64 years of age at year of reported data                                     |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)            | Low | Mid | High |
|  | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs in compulsory detention in closed settings in a 12 month period      | Low | Mid | High |
|  | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs in compulsory detention in closed settings at a single point in time | Low | Mid | High |
|  | NK  | NK  | NK   |

## ODT 7.3: Number of all drug users in compulsory detention sites for drug use

|  |     |     |      |
|--|-----|-----|------|
| Data reported  |     |     |      |
| Year of reported data  |     |     |      |
| Reference  |     |     |      |
| Adjustments  |     |     |      |
| Final/Adjusted data for 12 month period (to be used as indicator numerator)  |     |     |      |
| Final/Adjusted data for single point in time (to be used as indicator numerator)   |     |     |      |
| IDU prevalence estimate (%)  | Low | Mid | High |
|  |     |     |      |
| Reference  |     |     |      |
| General population 15-64 years of age at year of reported data   |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)                                  | Low | Mid | High |
|  | NK  | NK  | NK   |
| INDICATOR: Ratio of all drug users in compulsory detention in closed settings in a 12 month period : number of IDUs      | Low | Mid | High |
|  | NK  | NK  | NK   |
| INDICATOR: Ratio of all drug users in compulsory detention in closed settings at a single point in time : number of IDUs | Low | Mid | High |
|  | NK  | NK  |      |

**ODT: All documents reviewed**

No references recorded

## 4. HIV testing and counselling (T&C)

### T&C 1: Availability of HIV T&C

|                          |  |
|--------------------------|--|
| Is T&C available?        | Yes  |
| Most recent year of data | 2007   |
| Reference                | Country coordinating mechanism - Paraguay (2008). Strengthening the National Response in HIV/AIDS/STI in six health regions towards the universal access goal. Asuncion: 81. |

### T&C 2: Number of sites providing HIV T&C specifically targeting IDUs

|   |     |     |      |
|---|-----|-----|------|
| Data reported   |     |     |      |
| Year of reported data   |     |     |      |
| Reference   |     |     |      |
| Adjustments   |     |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data                          |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Number of targeted T&C sites per 1000 IDUs                                   | Low | Mid | High |
|   | NK  | NK  | NK   |

### T&C 3: Number of sites providing HIV T&C sites to the general population and also accessible to IDUs

|   |  |     |      |
|---|--|-----|------|
| Data reported   | VCT available but number not known   |     |      |
| Year of reported data   | 2007   |     |      |
| Reference   | Country coordinating mechanism - Paraguay (2008). Strengthening the National Response in HIV/AIDS/STI in six health regions towards the universal access goal. Asuncion: 81.   |     |      |
| Adjustments   |  |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 | NK   |     |      |
| IDU prevalence estimate (%)   | Low  | Mid | High |
|   | NK   | NK  | NK   |
| Reference   | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |     |      |
| General population 15-64 years of age at year of reported data                          | 3 687 626 (source: UN Population Division, 2009)   |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low  | Mid | High |
|   | NK   | NK  | NK   |
| INDICATOR: Number of all T&C sites per 1000 IDUs  | Low  | Mid | High |
|   | NK   | NK  | NK   |

**T&C 4: Number of Individual IDUs who were tested for HIV in 12 month period**

|   |     |     |      |
|---|-----|-----|------|
| Data reported   |     |     |      |
| Year of reported data   |     |     |      |
| Reference   |     |     |      |
| Adjustments   |     |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data                          |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of individual IDUs accessing T&Cs in a 12 month period            | Low | Mid | High |
|   | NK  | NK  | NK   |

**T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result**

|   |   |
|---|---|
| Year of reported data                       | 2007  |
| Reference                                   | WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO. |
| Data reported for both male and female IDUs | 12% IDUs received an HIV test in the last 12 months and know their results  |
| Adjustments                                 |   |
| Final/Adjusted data                         | 12.00%  |
| Data reported for male IDUs                 | 100% male IDUs received an HIV test in the last 12 months and know their results  |
| Adjustments                                 |   |
| Final/Adjusted data                         | 1   |
| Data reported for female IDUs               | 100% female IDUs received an HIV test in the last 12 months and know their results  |
| Adjustments                                 |   |
| Final/Adjusted data                         | 1   |

**T&C: All documents reviewed**

Country coordinating mechanism - Paraguay (2008). Strengthening the National Response in HIV/AIDS/STI in six health regions towards the universal access goal. Asuncion: 81.

UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362.

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

**5. Anti-retro-viral (ARV) treatment****ARV 1: Number of sites providing ARV treatment**

|   |   |            |             |
|---|---|------------|-------------|
| <b>Data reported</b>  | 5 sites   |            |             |
| <b>Year of reported data</b>  | 2008  |            |             |
| <b>Reference</b>  | WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.   |            |             |
| <b>Adjustments</b>  |   |            |             |
| <b>Final/Adjusted data (to be used as indicator numerator)</b>                                  | 5   |            |             |
| <b>IDU prevalence estimate (%)</b>  | <b>Low</b>  | <b>Mid</b> | <b>High</b> |
|   | NK  | NK         | NK          |
| <b>Reference</b>  | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |            |             |
| <b>General population 15-64 years of age at year of reported data</b>                           | 3 778 358 (source: UN Population Division, 2009)  |            |             |
| <b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>  | <b>Low</b>  | <b>Mid</b> | <b>High</b> |
|   | NK  | NK         | NK          |
| <b>HIV among IDU prevalence estimate (%)</b>  | <b>Low</b>  | <b>Mid</b> | <b>High</b> |
|   | 3.70  | 9.35       | 15          |
| <b>Reference</b>  | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.   |            |             |
| <b>Estimated number of HIV positive IDUs at year of reported data (to be used as indicator)</b> | <b>Low</b>  | <b>Mid</b> | <b>High</b> |
|   | NK  | NK         | NK          |
| <b>INDICATOR: Number of ARV treatment sites per 1000 IDUs</b>                                   | <b>Low</b>  | <b>Mid</b> | <b>High</b> |
|   | NK  | NK         | NK          |
| <b>INDICATOR: Number of ARV treatment sites per 1000 IDUs living with HIV</b>                   | <b>Low</b>  | <b>Mid</b> | <b>High</b> |
|   | NK  | NK         | NK          |

## ARV 2: Number of IDUs receiving ARVs at a single point in time

|  |   |      |      |
|--|---|------|------|
| Data reported  | Number of IDUs on ART not known   |      |      |
| Year of reported data  | 2008  |      |      |
| Reference  | WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.   |      |      |
| Adjustments  |   |      |      |
| Final/Adjusted data (to be used as indicator numerator)  | NK  |      |      |
| IDU prevalence estimate (%)  | Low   | Mid  | High |
|  | NK  | NK   | NK   |
| Reference  | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.<br><br>Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008. |      |      |
| General population 15-64 years of age at year of reported data                                       | 3 778 358 (source: UN Population Division, 2009)  |      |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator)              | Low   | Mid  | High |
|  | NK  | NK   | NK   |
| HIV among IDU prevalence estimate (%)  | Low   | Mid  | High |
|  | 3.70  | 9.35 | 15   |
| Reference  | Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.   |      |      |
| Estimated number of HIV positive IDUs at year of reported data (to be used as indicator denominator) | Low   | Mid  | High |
|  | NK  | NK   | NK   |
| INDICATOR: Ratio of IDUs on ART: 100 IDUs living with HIV  | Low   | Mid  | High |
|  | NK  | NK   | NK   |

## ARV 3: Restrictions on IDUs' access to ARVs

|  |  |
|--|--|
| Do restrictions exist which limit IDUs' access to ARV treatment? |  |
| Year of reported data  |  |
| Reference  |  |

**ARV: All documents reviewed**

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

## 6. Condoms

### Condoms 1: Availability of condom programs targeting IDUs

|   |  |
|---|--|
| Are condom programs targeting IDUs available? |  |
| Comments                                      |  |
| Year  |  |
| Reference                                     |  |

### Condoms 2: Number of sites distributing condoms to IDUs

|   |     |     |      |
|---|-----|-----|------|
| Data reported   |     |     |      |
| Year of reported data   |     |     |      |
| Reference   |     |     |      |
| Adjustments   |     |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data                          |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Number of condom distribution sites targeting IDU per 1000 IDUs              | Low | Mid | High |
|   | NK  | NK  | NK   |

### Condoms 3: Number of individual IDUs receiving condoms

|   |     |     |      |
|---|-----|-----|------|
| Data reported   |     |     |      |
| Year of reported data   |     |     |      |
| Reference   |     |     |      |
| Adjustments   |     |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data                          |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Percentage of IDUs receiving condoms in a 12 month period                    | Low | Mid | High |
|   | NK  | NK  | NK   |

## Condoms 4: Number of condoms distributed to IDUs

|   |     |     |      |
|---|-----|-----|------|
| Data reported   |     |     |      |
| Year of reported data   |     |     |      |
| Reference   |     |     |      |
| Adjustments   |     |     |      |
| Final/Adjusted data (to be used as indicator numerator)                                 |     |     |      |
| IDU prevalence estimate (%)   | Low | Mid | High |
|   |     |     |      |
| Reference   |     |     |      |
| General population 15-64 years of age at year of reported data                          |     |     |      |
| Estimated number of IDUs at year of reported data (to be used as indicator denominator) | Low | Mid | High |
|   | NK  | NK  | NK   |
| INDICATOR: Total number of condoms distributed per 12 month period per IDU              | Low | Mid | High |
|   | NK  | NK  | NK   |

**Condoms: All documents reviewed**

Country coordinating mechanism - Paraguay (2008). Strengthening the National Response in HIV/AIDS/STI in six health regions towards the universal access goal. Asuncion: 81.